ZTS · Zoetis Inc.

240 filings

ZTS SEC Filings

Zoetis Inc. - 240 total filings

Filing record · 2016–202610-K1110-Q338-K135

Showing 1–50 of 240 filings

Zoetis Inc. 8-K Report, Executive Changes (Oct 13, 2026)

Zoetis Inc. (NYSE: ZTS) filed a Form 8-K on October 13, 2026 disclosing the appointment of Iris Knobloch to its Board of Directors, effective December 1, 2026. Under Item 5.02, the Board appointed Ms. Knobloch on October 8, 2026, to serve on the Corporate Governance Committee, and the Board size will expand from twelve to thirteen members. The filing states she was not selected under any arrangement with a third party and has no reportable related-party transactions. She will receive the standard non-employee director compensation and enter into the Company's standard indemnification agreement. The appointment is a governance event rather than a financial one. The filing contains no financial results, guidance, M&A activity, or changes to executive management, and it does not affect Zoetis's reported financials or operations. Investors should view it as routine board refreshment, with the most notable element being the addition of a director with consumer, digital, and international media experience to a company in animal health. Ms. Knobloch's current board seats at Deezer, Lazard, and Vail Resorts, along with her past roles, could be relevant to how the board addresses consumer strategy and digital initiatives. The Company's CEO, Kristin Peck, and Board Chair, Michael McCallister, both praised the appointment, linking it to the Company's innovation strategy, customer engagement, and new ways to reach pet owners. The Item 7.01 press release is furnished, not filed, and carries no material new financial information. Overall, the filing is low-impact for near-term valuation and fundamentals.

Oct 13, 2026 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 8, 2026)

Zoetis Inc. (ZTS) has announced a quarterly dividend payment of $0.53 per share for the fourth quarter of 2026. This declaration, made on October 8, 2026, signals continued commitment to returning capital to shareholders. The dividend is scheduled to be paid on December 1, 2026, to shareholders of record as of October 30, 2026. This information is being disclosed under Regulation FD and is accompanied by a press release. While this filing focuses solely on the dividend declaration and does not provide updates on financial performance or strategic initiatives, it represents a regular step in Zoetis' capital allocation strategy. Investors seeking to participate in this dividend should ensure their holdings are registered by the specified record date. The company has also included the standard cover page interactive data file in its filing.

Oct 8, 2026 10-Q

Zoetis Inc. Quarterly Report for Q2 Ended Jun 30, 2026

Zoetis Inc. reported a slight revenue decrease of 0.2% to $2,468 million for the three months ended June 30, 2026, compared to $2,474 million in the prior year period. This was driven by a 2% operational decrease, partially offset by a favorable foreign exchange impact. For the six months ended June 30, 2026, revenue grew 1% to $4,730 million from $4,672 million in the prior year, also benefiting from foreign exchange. Net income attributable to Zoetis Inc. decreased by 4.8% to $691 million for the quarter and by 2.8% to $1,292 million for the six months, reflecting increased restructuring charges and other costs. The company announced a definitive agreement to acquire Neogen's animal genomics business, expected to close in the second half of 2026. The U.S. segment experienced a revenue decline of 7% for both the quarter and the six months, primarily due to softer demand and increased competition in the companion animal market, though livestock product sales showed growth. The International segment performed more robustly, with revenue increasing by 8% for the quarter and 12% for the six months, driven by strong growth in both companion animal and livestock products, further boosted by favorable foreign exchange rates. The company continues to actively manage its financial resources, evidenced by its robust credit facility and a significant share repurchase program. Zoetis Inc. also highlighted progress in its ongoing business process transformation program, including the Fiscal Year Alignment for its international subsidiaries. Despite some headwinds in the U.S. market, the company's diversified product portfolio and international expansion, coupled with strategic acquisitions like the Neogen animal genomics business, position it for continued resilience and growth.

Aug 6, 2026 8-K

Zoetis Inc. 8-K Report, Executive Changes (Aug 6, 2026)

Zoetis (ZTS) announced that James "Jay" Saccaro will become Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. The role is newly created and combines the global finance function (capital allocation, financial strategy, reporting and controls, investor engagement) with oversight of Global Manufacturing and Supply. Saccaro will be the principal financial and principal accounting officer. He comes from GE HealthCare, where he has been CFO since June 2023, and previously spent roughly eight years as CFO of Baxter International. The 8-K also reports a planned CFO transition: Wetteny Joseph, the current EVP and CFO, will step down from the executive role after August 16, 2026 and remain a non-executive officer until the earlier of February 28, 2027 or a mutually agreed date. The company states his departure was not due to any disagreement on operations, policies, practices, accounting, or internal controls. Saccaro's compensation package includes a $1,000,000 base salary, a 100% of salary target bonus (2026 paid at target and pro-rated), and a $5,000,000 annual long-term incentive target (50% PSUs, 25% RSUs, 25% stock options). He also receives a one-time make-whole RSU award with a $6,250,000 grant-date value vesting in thirds over three years, plus a $1,250,000 one-time cash award subject to repayment if he is terminated under certain circumstances within his first year. Joseph will keep his base salary, benefits and equity vesting through his termination date, may earn a 2026 annual incentive at target subject to company performance funding, and will receive Executive Severance Plan benefits on departure. His outstanding equity will be treated as a Restructuring Event. For investors, the key points are continuity of finance leadership through a planned handover and the expanded mandate, which places manufacturing and supply under the CFO and signals a focus on operational execution alongside capital allocation. The filing does not discuss financial results or guidance changes. The make-whole awards and the planned CEO-level reporting of Joseph as a special advisor on financial matters through early 2027 suggest a deliberately managed transition rather than an abrupt departure.

Aug 6, 2026 8-K

Zoetis Inc. 8-K Report, Financial Results (Aug 6, 2026)

Zoetis reported second quarter 2026 results on August 6, 2026, with revenue flat year over year at $2.5 billion ($2,468 million) on a reported basis and down 1% on an organic operational basis. GAAP net income was $691 million, or $1.65 per diluted share, down 5% in dollars but up 1% per share thanks to a lower share count (417.7 million diluted shares versus 445.5 million a year earlier). Adjusted net income was $781 million, or $1.87 per diluted share, down 2% organically. The quarter was dominated by weakness in the U.S. Companion Animal business, where revenue fell 11% on softer end-market demand, pricing pressure on the dermatology franchise and Simparica Trio, and generic competition for Cerenia and Convenia. Livestock (up 23% in the U.S.) and International growth (up 6% organically) partly offset the decline. The more significant news for investors is the guidance cut. Full-year 2026 revenue guidance was lowered to $9.120-$9.320 billion, implying organic operational growth of (3)% to (1)%, down from the prior 2% to 5% range given in May. Adjusted diluted EPS guidance was reduced to $6.15-$6.25 from $6.85-$7.00, and reported diluted EPS guidance to $5.55-$5.65 from $6.35-$6.50. Management attributed the revision to a more pressured Companion Animal market, including lower clinic visits, pet owner price sensitivity, and heightened competition. The company also flagged higher restructuring and cost-reduction charges, with certain significant items and acquisition-related costs now expected to total about $150 million, up from $100 million. Management is responding with targeted commercial investments, accelerated innovation, and business development. The company highlighted new approvals and launches, including Lenivia and Portela (long-acting osteoarthritis pain antibodies), Dectomax-CA1 as the first FDA conditional approval for New World screwworm, and the VitalRADS teleradiology acquisition. Investors should weigh these pipeline and diversification efforts against near-term earnings pressure, the sharp guidance reduction, and the ongoing Companion Animal headwinds.

Aug 6, 2026 8-K

Zoetis Inc. 8-K Report, Executive Changes (May 22, 2026)

Zoetis Inc. (ZTS) filed an 8-K on May 22, 2026, reporting on its 2026 Annual Meeting of Shareholders held on May 20, 2026. The filing details the outcomes of five proposals voted on by shareholders, with a notable 90.13% of outstanding shares represented, indicating strong shareholder engagement. The meeting also marked the retirement of Ms. Louise M. Parent from the Board of Directors in accordance with the company's retirement policy. Key outcomes include the overwhelming re-election of all twelve director nominees, demonstrating continued confidence in the board's leadership. Shareholders also approved, on an advisory basis, the executive compensation program and affirmed the preference for an annual advisory vote on executive compensation. The appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was ratified. However, a shareholder proposal to permit action by written consent was not approved.

May 22, 2026 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 20, 2026)

Zoetis Inc. (ZTS) has announced a quarterly dividend of $0.53 per share for the third quarter of 2026. This announcement, made on May 20, 2026, provides a clear income stream update for its shareholders. The dividend payment is scheduled for September 1, 2026, with a record date of July 20, 2026, ensuring that investors holding the stock by mid-July will be eligible to receive this payout.

May 20, 2026 10-Q

Zoetis Inc. Quarterly Report for Q1 Ended Mar 31, 2026

Zoetis Inc. reported first-quarter 2026 results with total revenue of $2,262 million, a 3% increase year-over-year. This growth was driven by price increases and contributions from other in-line products, partially offset by volume decreases in key franchises and the impact of the MFA divestiture. The company experienced a favorable foreign currency impact of 4% on reported revenue growth. Net income attributable to Zoetis Inc. was $601 million, a slight decrease of 1% compared to the prior year's $602 million. Diluted earnings per share remained flat at $1.42. The company highlighted a shift in its international segment's revenue growth, with operational revenue increasing by 9%, favorably impacted by foreign exchange. Zoetis also announced an agreement to acquire Neogen's animal genomics business, expected to close in the second half of 2026.

May 7, 2026 8-K

Zoetis Inc. 8-K Report, Financial Results (May 7, 2026)

Zoetis (ZTS) reported first quarter 2026 results that came in below management's expectations, with the company citing a more challenging operating environment. Revenue rose 3% reported to $2.262 billion but was flat on an organic operational basis. Reported net income was $601 million ($1.42 diluted EPS), while adjusted net income reached $646 million ($1.53 adjusted diluted EPS, up 9% reported and 7% organic operational). The U.S. segment was a clear weak spot, with revenue down 8% driven by an 11% decline in companion animal sales from competitive pressure in dermatology and Simparica Trio, pet owner price sensitivity, lower veterinary visits, generic competition on Convenia and Cerenia, and lower Librela sales. International revenue grew 17% reported (10% organic operational), and livestock grew 15% reported, partly helped by an estimated $100 million benefit from the Fiscal Year Alignment and timing of price increases. Management lowered full-year 2026 guidance. Revenue is now expected at $9.680 to $9.960 billion (2% to 5% organic operational growth), adjusted net income at $2.870 to $2.950 billion (2% to 6% organic growth), and adjusted diluted EPS at $6.85 to $7.00. Reported diluted EPS guidance is $6.35 to $6.50. Investors should note that the Fiscal Year Alignment, which eliminated the one-month reporting lag for non-U.S. subsidiaries and retroactively recast prior periods, complicates year-over-year comparisons and flatters International growth in the quarter. Strategically, Zoetis continues to point to a pipeline of more than 12 potential blockbusters and a planned acquisition of Neogen's animal genomics business, expected to close in the second half of 2026. Restructuring and certain significant items totaled $27 million pre-tax in the quarter, primarily employee termination costs tied to organizational refinements, signaling ongoing cost actions alongside the commercial reset.

May 7, 2026 8-K

Zoetis Inc. 8-K Report, Financial Results (Feb 12, 2026)

Zoetis reported Q4 and full-year 2025 results on February 12, 2026. For Q4, revenue rose 3% to $2.39 billion (4% organic operational growth), and reported net income rose 4% to $603 million, or $1.37 per diluted share. Adjusted diluted EPS was $1.48, up 6% on a reported basis. For full-year 2025, revenue reached $9.47 billion (up 2% reported, 6% organic operational), reported EPS was $6.02 (up 10%), and adjusted EPS was $6.41 (up 8%). Growth was led by Companion Animal, which rose 5% for the year, while Livestock declined 5% reported (up 3% organic) largely because of the divestiture of the medicated feed additive portfolio. Quality of the Q4 International beat warrants scrutiny. Management disclosed that the operational changes tied to the elimination of the one-month reporting lag (the "Expected Fiscal Year Alignment") pulled roughly 2.5% to 3.5% of International segment sales into Q4 2025, and it does not expect that effect to recur at fiscal year-end 2026. The company also shifted the timing of annual price increases in certain International subsidiaries into 2026 and delayed processing of some December 2025 orders into 2026. Investors should therefore treat part of Q4 growth as timing-driven rather than underlying demand. For 2026, Zoetis guided to revenue of $9.825 to $10.025 billion, with 3% to 5% organic operational growth, and adjusted diluted EPS of $7.00 to $7.10 (reported EPS of $6.65 to $6.75). Pipeline news included first approvals for long-acting OA pain products Lenivia (dogs) and Portela (cats) in Canada and the EU, with launches planned this year. The guidance reflects January 20, 2026 foreign exchange rates and about $65 million of expected significant items and acquisition-related costs.

Feb 12, 2026 10-K

Zoetis Inc. Annual Report, Year Ended Dec 31, 2025

Zoetis Inc. reported solid financial results for the fiscal year ended December 31, 2025, with total revenue reaching $9.47 billion, a 2% increase year-over-year, driven by a 3% operational revenue growth. This growth was primarily attributed to price increases and contributions from key product franchises, partially offset by the impact of a divestiture. Net income grew 8% to $2.67 billion. The company continues to demonstrate strength in both its U.S. and International segments, with companion animal products representing a significant 70% of total revenue. Key product lines like Simparica/Simparica Trio and Apoquel/Apoquel Chewable remain strong contributors, accounting for a substantial portion of overall revenue. Zoetis also continues to invest in research and development, with expenses totaling $698 million, focusing on both new product development and lifecycle innovation. The company's balance sheet remains robust, with total assets growing to $15.47 billion. Zoetis actively manages its capital structure, including a significant share repurchase program of up to $6 billion, demonstrating a commitment to returning value to shareholders. The company's financial health is supported by a strong credit facility and diverse revenue streams across multiple species and product categories. Looking ahead, Zoetis is focused on its strategic pillars of innovation, customer experience, digital solutions, talent development, sustainability, and operational excellence to drive continued growth in the dynamic animal health market.

Feb 12, 2026 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 5, 2026)

Zoetis Inc. (ZTS) has filed a Current Report (8-K) on February 5, 2026, primarily announcing its second-quarter 2026 dividend declaration. The company has declared a dividend of $0.53 per share, which is a positive signal to investors regarding the company's financial health and commitment to returning capital to shareholders. This dividend payment is scheduled for June 2, 2026, with a record date of April 20, 2026, providing clear timelines for eligible shareholders.

Feb 5, 2026 8-K

Zoetis Inc. 8-K Report, Material Agreement (Dec 18, 2025)

On December 18, 2025, Zoetis completed a $2.0 billion private offering of 0.25% Convertible Senior Notes due June 15, 2029, including the $250 million over-allotment option that was exercised in full. Net proceeds are approximately $1,969.6 million. The company plans to use roughly $186.6 million for capped call transactions, $248.0 million for a privately negotiated repurchase of about 2.1 million shares, and the remaining approximately $1,535.0 million for additional open-market or privately negotiated buybacks under its existing $6 billion repurchase program, expected to be completed by Q1 2026. The effect is a large, debt-funded share repurchase that is designed to be largely offset in dilution terms by the capped calls. The notes carry a low 0.25% coupon and an initial conversion price of about $148.20, a 22.5% premium to the December 15, 2025 closing price. Zoetis has the option to settle conversions in cash, shares, or a combination, and it must pay cash at least up to principal. The capped calls, with a $211.72 cap (75% premium), cover roughly 13.5 million shares and are intended to reduce dilution up to that price. The maximum potential share issuance is about 13.5 million shares, or 16.5 million including make-whole adjustments. The notes are senior unsecured obligations, and the filing discloses a waiver under the revolving credit facility that permits early conversions. For investors, the transaction shifts the capital structure toward low-cost convertible debt and reduces the share count in the near term, which can support per-share metrics. Key risks include the added leverage of roughly $2 billion, potential hedge-related trading activity around conversion or repurchase windows, and the execution of the buyback program over the coming months. The filing is a financing and capital-allocation event rather than a change in operating performance.

Dec 18, 2025 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 11, 2025)

Zoetis Inc. (ZTS) has announced its first-quarter 2026 dividend, demonstrating a consistent commitment to returning capital to shareholders. The company declared a dividend of $0.53 per share, payable on March 3, 2026, to shareholders of record as of January 20, 2026. This regular dividend payment is a key indicator of the company's financial stability and its confidence in sustained profitability. While this filing is primarily a Regulation FD disclosure regarding the dividend, it underscores Zoetis' ongoing capital allocation strategy. Investors should view this as a positive signal of the company's financial health and its ability to generate consistent cash flows to support shareholder returns. Further analysis of Zoetis' broader financial performance, strategic initiatives, and market position would be necessary for a complete investment assessment.

Dec 11, 2025 8-K

Zoetis Inc. 8-K Report, Corporate Update (Dec 2, 2025)

Zoetis Inc. (ZTS) filed a Form 8-K on December 2, 2025 furnishing the presentation for its Innovation Webcast, held that morning at 8:30 a.m. ET. The filing is informational under Item 8.01 (Other Events) and contains no new financial results, guidance changes, or material agreements. Its substance is a strategic update on the company's long-term growth narrative, which management frames around a Animal Health market expected to reach roughly $90 billion by 2035, up from about $50 billion in 2024. Management's key message is that growth is being driven by two structural tailwinds: companion animal demand (premiumization, pet longevity, and advanced therapies such as JAK inhibitors and monoclonal antibodies) and livestock demand (rising protein consumption and a shift toward preventive vaccines). The presentation emphasizes Zoetis's R&D model, citing R&D investment of $686 million in 2024 (7.4% of revenue, up from $463 million in 2020), a pipeline with expected major approvals each year through the late 2020s, and new therapeutic areas in chronic kidney disease, oncology, and cardiology, which management estimates together represent $5 billion or more in total addressable market. The company reported 2024 adjusted EBITDA of $3.8 billion (41% of revenue) and adjusted net income of $2.7 billion. For investors, the filing offers management's long-term framework rather than near-term catalysts. Its forward-looking statements are extensive, and the presentation's targets (such as the $90 billion market projection and the new-market TAM figures) are internal estimates subject to regulatory, competitive, and execution risk. Investors should weigh these long-range claims against the company's upcoming quarterly results and pipeline milestones.

Dec 2, 2025 8-K

Zoetis Inc. 8-K Report, Financial Results (Nov 4, 2025)

Zoetis (NYSE: ZTS) reported third quarter 2025 results on November 4, 2025, showing modest top-line growth that was offset by a meaningful reduction in full-year revenue guidance. Reported revenue was $2.4 billion, up 1% year over year, with organic operational growth of 4%. Reported net income attributable to Zoetis was $721 million, or $1.63 per diluted share, up 6% and 9% respectively. Adjusted net income was $754 million, or $1.70 per diluted share, up 9% on an organic operational basis. Growth in the U.S. segment was driven by parasiticides, diagnostics and dermatology, offset by declines in the osteoarthritis monoclonal antibodies (Librela and Solensia) and the divestiture of the medicated feed additive portfolio. International revenue grew 6% organically, led by companion animal products. The key investor takeaway is the guidance revision. Management lowered full-year 2025 revenue guidance to $9.400–$9.475 billion, with organic operational growth of 5.5%–6.5%, down from $9.450–$9.600 billion and 6.5%–8% previously, citing broader macro trends and the operating environment in the back half of the year. Organic operational adjusted net income growth was narrowed to 5.5%–7.0% from 5.5%–7.5%. Adjusted diluted EPS guidance was maintained at $6.30–$6.40, supported by cost discipline, with adjusted SG&A guidance reduced and the adjusted cost of sales ratio guided to approximately 28.3% of revenue. Management also highlighted regulatory progress, including Lenivia (a long-acting OA pain mAb for dogs) approved in Canada with EU marketing authorization expected in Q4 2025, Portela approved in the EU for cats, and a conditional FDA approval for Dectomax-CA1 against New World screwworm. Management plans an Innovation webcast on December 2, 2025. The filing states that management expects a significant approval in a major market each year for the next several years.

Nov 4, 2025 10-Q

Zoetis Inc. Quarterly Report for Q3 Ended Sep 30, 2025

Zoetis Inc. reported solid financial results for the nine months ended September 30, 2025, with revenue increasing by 2% to $7.08 billion and net income attributable to Zoetis Inc. growing by 9% to $2.07 billion. This growth was driven by a combination of price increases and volume growth in key franchises, partially offset by the impact of a divestiture. The company demonstrated improved cost management, with Cost of Sales as a percentage of revenue decreasing from 29.0% to 27.6% year-over-year for the nine-month period. Key financial highlights include a robust increase in diluted Earnings Per Share (EPS) by 11% to $4.65 for the nine-month period. The company also managed its balance sheet effectively, with cash and cash equivalents increasing to $2.08 billion and a strong working capital position. Zoetis maintained compliance with its debt covenants and has a significant authorization remaining for its share repurchase program, indicating a continued focus on returning value to shareholders.

Nov 4, 2025 8-K

Zoetis Inc. 8-K Report, Executive Changes (Oct 28, 2025)

Zoetis Inc. (NYSE: ZTS) filed an 8-K on October 28, 2025 reporting a board appointment rather than a financial or operational event. Under Item 5.02, the Board appointed Stephanie Tilenius as a director effective December 1, 2025, and increased the Board size from twelve to thirteen members at the same time. The filing states she was not selected under any third-party arrangement and has no reportable related-party transactions. She will join the company's standard non-employee director compensation program and sign the Company's standard indemnification agreement. Under Item 7.01, the Company also furnished a press release (Exhibit 99.1) announcing the appointment. The release highlights Ms. Tilenius's background in digital health, AI, and technology. She founded and served as CEO of Vida Health (2014-2023), a B2B chronic care platform for diabetes and obesity, and previously held senior roles at Google, PayPal, and eBay. She currently sits on the board of Seagate Technology Holdings plc. The release frames her addition as support for Zoetis's digital transformation and data-driven innovation strategy. The Item 7.01 material is furnished, not filed, so it is not subject to Exchange Act liability. For investors, this is a governance update with no disclosed impact on financial results, guidance, or capital allocation. The filing's significance lies mainly in the signal of strategic emphasis on digital and AI capabilities, which the company paired with the board expansion. Investors may want to watch whether the company follows this with concrete digital or AI initiatives in future earnings commentary.

Oct 28, 2025 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 9, 2025)

Zoetis Inc. (ZTS) has filed a current report (8-K) on October 9, 2025, primarily announcing the declaration of its fourth-quarter 2025 dividend. This dividend amounts to $0.50 per share, providing a direct return of capital to shareholders. The payment date is scheduled for December 2, 2025, with a record date of October 31, 2025. This announcement is a routine event for investors seeking income from their ZTS holdings. While this filing is limited in scope, focusing on the dividend declaration, it's important for shareholders to note the ex-dividend and payment dates to ensure they are holders of record in time to receive the payout. The company has also provided the standard disclaimer that the information is not deemed 'filed' for regulatory purposes unless specifically incorporated into other filings.

Oct 9, 2025 8-K

Zoetis Inc. 8-K Report, Material Agreement (Aug 27, 2025)

Zoetis Inc. (ZTS) has announced the execution of a new $1.25 billion senior unsecured revolving credit facility, effective August 27, 2025. This facility, which matures in five years, replaces the company's previous credit agreement and provides enhanced financial flexibility with an option to increase the total commitment to $1.75 billion. The new credit line offers competitive borrowing terms, with interest rates tied to SOFR or a base rate plus an applicable margin, and includes a facility fee on commitments. The agreement's covenants focus on maintaining a maximum total leverage ratio and include standard restrictions on asset sales, mergers, and incurring priority debt, which are typical for a company of Zoetis's financial standing. The termination of the prior credit agreement, originally set to expire in December 2027, signifies a strategic move by Zoetis to optimize its capital structure and ensure access to liquidity on favorable terms. This proactive refinancing demonstrates the company's commitment to maintaining a strong balance sheet and its ability to secure robust financing arrangements to support its ongoing operations and strategic growth initiatives. Investors can view this as a positive development, indicating sound financial management and a focus on operational efficiency.

Aug 27, 2025 8-K

Zoetis Inc. 8-K Report, Corporate Update (Aug 18, 2025)

Zoetis Inc. (ZTS) has filed an 8-K report detailing a significant debt financing event. On August 11, 2025, the company entered into an Underwriting Agreement to issue and sell $850 million of 4.150% Senior Notes due 2028 and $1 billion of 5.000% Senior Notes due 2035, totaling $1.85 billion in aggregate principal amount. These notes were issued under an existing indenture supplemented by a seventh supplemental indenture, with Deutsche Bank Trust Company Americas acting as the trustee. The offering was registered on Form S-3. This transaction represents a substantial capital raise for Zoetis, likely intended to fund ongoing operations, strategic initiatives, or potential acquisitions. Investors should note the specific interest rates and maturity dates for each tranche of notes, which will impact the company's future interest expense and debt repayment obligations. The filing provides detailed exhibits regarding the underwriting agreement and the indentures governing these new senior notes.

Aug 18, 2025 8-K

Zoetis Inc. 8-K Report, Financial Results (Aug 5, 2025)

Zoetis reported second-quarter 2025 results on August 5, 2025, with revenue of $2.46 billion, up 4% reported and 8% on an organic operational basis, and GAAP net income of $718 million ($1.61 diluted EPS), up 15% and 18% respectively. Adjusted net income was $783 million, or $1.76 per diluted share, up 10% and 13%. Growth was led by the U.S. and International companion animal franchises, particularly Simparica Trio and dermatology products such as Apoquel and Cytopoint. Livestock was the weak spot, down 8% reported, reflecting the divestiture of the medicated feed additive portfolio and competitive pressure on Draxxin, while the Librela and Solensia osteoarthritis pain mAbs also declined in the U.S. Management raised full-year 2025 guidance across the board. Revenue is now expected at $9.450 to $9.600 billion, up from $9.425 to $9.575 billion, with organic operational growth of 6.5% to 8.0%. Adjusted diluted EPS guidance rose to $6.30 to $6.40 from $6.20 to $6.30, and adjusted net income guidance rose to $2.825 to $2.875 billion. Reported diluted EPS guidance is $5.90 to $6.00, reflecting roughly $0.40 of significant items and purchase accounting. Guidance assumes late-July foreign exchange rates and reflects enacted and announced tariffs. For investors, the quarter shows broad-based organic growth and disciplined cost management, with adjusted cost of sales falling to 26.3% of revenue from 28.3%. Reported results carry a notable gap to adjusted figures, driven by purchase accounting, restructuring, and a business process transformation program, so investors should weigh both GAAP and non-GAAP measures. The filing is furnished under Item 2.02 rather than filed, so its contents are not incorporated into Securities Act registration statements.

Aug 5, 2025 10-Q

Zoetis Inc. Quarterly Report for Q2 Ended Jun 30, 2025

Zoetis Inc. reported solid financial results for the second quarter and first half of 2025. Revenue increased by 4% to $2.46 billion for the quarter and 3% to $4.68 billion for the first half, demonstrating continued growth driven by price increases and strong performance in key franchises, particularly in companion animal products. Diluted earnings per share also saw a significant increase, rising to $1.61 for the quarter and $3.02 for the half, up from $1.37 and $2.68 respectively in the prior year periods. This growth reflects effective cost management, including a reduction in the cost of sales as a percentage of revenue, and a strategic focus on higher-margin products. The company continues to navigate a dynamic global environment, with operational revenue growth outpacing reported growth due to unfavorable foreign exchange rates. Despite these headwinds, Zoetis maintains a strong financial position, evidenced by healthy operating cash flow and a robust balance sheet. The company also highlighted ongoing investments in research and development to fuel future innovation and maintain its leadership position in the animal health sector. Shareholder returns remain a priority, with continued share repurchases under its authorized program.

Aug 5, 2025 8-K

Zoetis Inc. 8-K Report, Executive Changes (May 22, 2025)

Zoetis Inc. (NYSE: ZTS) filed this 8-K to report governance changes and the results of its May 21, 2025 Annual Meeting of Shareholders. Robert Scully retired from the Board effective May 21, 2025, under the company's director retirement policy, and Dr. Mark Stetter, Dean of the University of California, Davis School of Veterinary Medicine, was elected to the Board at the meeting. He will serve on the Quality and Innovation Committee. The filing contains no financial results, guidance, or operating metrics. Its investor relevance is governance and shareholder sentiment. Shareholders approved all three company-backed proposals. Holders representing 88.08% of eligible voting power attended, well above the quorum requirement. All twelve director nominees were re-elected to one-year terms, and the non-binding say-on-pay advisory vote passed, with roughly 90% of votes cast in favor (334.2 million for vs. 35.2 million against). KPMG LLP was ratified as the independent auditor for fiscal 2025. The one shareholder proposal on special shareholder meetings failed decisively, with about 86% of votes cast against (320.7 million against vs. 50.4 million for). The results point to broadly strong shareholder support for management and the Board. Director support was generally high, although Gregory Norden (about 93% for), Michael McCallister (about 96%), and Frank D'Amelio (about 94%) drew the largest against-vote totals among the nominees. The defeat of the special-meeting proposal suggests shareholders did not want to change the company's current governance terms on that issue.

May 22, 2025 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 21, 2025)

Zoetis Inc. (ZTS) has filed an 8-K report on May 21, 2025, primarily disclosing a regular quarterly dividend declaration. The company announced a dividend of $0.500 per share for the third quarter of 2025. This action signals continued confidence in the company's financial health and its commitment to returning value to shareholders. Investors should note the payment date of September 3, 2025, and the record date of July 18, 2025, for eligibility. While this filing does not contain new financial performance data or strategic shifts, the consistent dividend payout is a positive indicator for income-focused investors. The declaration aligns with Zoetis's established practice of providing regular returns, suggesting stable operational performance and a solid cash flow generation capability. Investors seeking income from their ZTS holdings can anticipate this distribution as per the announced schedule.

May 21, 2025 8-K

Zoetis Inc. 8-K Report, Financial Results (May 6, 2025)

Zoetis (ZTS) reported first quarter 2025 revenue of $2.22 billion, up 1% on a reported basis but up 9% on an organic operational basis, which excludes foreign exchange and divestitures. Reported net income rose 5% to $631 million ($1.41 diluted EPS, up 8%). Adjusted net income was $662 million, or $1.48 per diluted share, up 4% and 7% reported and 6% organic operational. Growth was led by Companion Animal, which rose 9% organically, with Simparica Trio, Apoquel, Cytopoint, Librela and Solensia as key drivers. Livestock declined 10% on a reported basis, largely due to the divestiture of the medicated feed additive portfolio, though it rose 7% organically. Full-year 2025 guidance was mixed. Revenue guidance was raised to $9.425-$9.575 billion from $9.225-$9.375 billion, mainly reflecting foreign exchange, while organic operational revenue growth of 6-8% was maintained. Adjusted diluted EPS guidance was raised to $6.20-$6.30 from $6.00-$6.10. Management did, however, lower organic operational growth in adjusted net income to 5-7% from 6-8%, citing enacted tariffs. Reported diluted EPS guidance is $5.85-$5.95, and the adjusted cost of sales ratio was raised to roughly 28.5% from about 28.0%. The key investor takeaway is strong underlying demand in Companion Animal and International markets, offset by tariff headwinds and a higher cost base. The gap between reported and adjusted EPS guidance (about $0.35 at the midpoint) reflects purchase accounting and significant items that investors should monitor.

May 6, 2025 10-Q

Zoetis Inc. Quarterly Report for Q1 Ended Mar 31, 2025

Zoetis Inc. reported revenue of $2,220 million for the first quarter of 2025, a slight increase of 1% compared to $2,190 million in the prior year period. On an operational basis, excluding foreign exchange impacts, revenue grew by 5%. This growth was driven by a 4% increase in pricing and a 4% volume increase from key franchises, partially offset by a 4% decrease related to the divestiture of its medicated feed additive (MFA) portfolio. Net income attributable to Zoetis Inc. rose by 5% to $631 million, or $1.41 per diluted share, up from $599 million, or $1.31 per diluted share, in the first quarter of 2024. The company's effective tax rate increased to 22.1% from 19.8%, impacting profitability. The company experienced a notable shift in its revenue mix, with companion animal products showing robust growth (up 7% overall, 9% operationally) while livestock products saw a decline (down 10% overall, 5% operationally). This is largely attributable to the MFA divestiture impacting livestock sales. Geographically, the U.S. segment saw a 2% revenue increase driven by companion animal products, while the International segment's revenue was flat overall but grew 7% operationally, with both companion animal and livestock segments contributing positively on an operational basis. The company continued its share repurchase program, buying back $443 million worth of stock in the quarter.

May 6, 2025 8-K

Zoetis Inc. 8-K Report, Financial Results (Feb 13, 2025)

Zoetis Inc. (NYSE: ZTS) reported fourth quarter and full year 2024 results on February 13, 2025, and issued full year 2025 guidance. Q4 2024 revenue was $2.3 billion, up 5% reported and 6% operationally, with reported net income of $581 million ($1.29 per diluted share, up 11% and 13%). Adjusted net income was $632 million, or $1.40 per diluted share. For full year 2024, revenue reached $9.3 billion (up 8% reported, 11% operational), reported net income was $2.5 billion ($5.47 per diluted share), and adjusted diluted EPS was $5.92. Operational growth in adjusted net income was 15% for the year, and organic operational revenue growth was 12%, which excludes the October 2024 divestiture of the medicated feed additive portfolio and certain water-soluble products. The key forward-looking item is 2025 guidance: revenue of $9.225 to $9.375 billion, implying 2% to 4% operational growth and 6% to 8% organic operational growth. Reported diluted EPS is guided at $5.70 to $5.80 and adjusted diluted EPS at $6.00 to $6.10. Adjusted net income is expected to be $2.700 to $2.750 billion. Management attributes the outlook to continued demand for its franchises, with companion animal products (such as Simparica Trio, Apoquel/Cytopoint, and the Librela and Solensia osteoarthritis mAbs) driving growth, while livestock products were weaker in Q4, particularly in the U.S. Investors should note the gap between reported and adjusted EPS in 2025 (roughly $0.23 of purchase accounting and about $0.07 of significant items and deal costs), and that the divestiture is depressing reported revenue growth against the prior year. The filing is furnished under Item 2.02 and is not deemed filed under the Exchange Act.

Feb 13, 2025 10-K

Zoetis Inc. Annual Report, Year Ended Dec 31, 2024

Zoetis Inc. reported strong financial performance for the fiscal year ended December 31, 2024, with total revenue reaching $9.26 billion, an increase of 8% year-over-year. This growth was driven by an 11% operational revenue increase, fueled by price adjustments (6%) and volume growth from new products and key dermatology products (3% and 2% respectively). The company's U.S. segment showed robust growth of 11%, while the International segment experienced a 5% increase in revenue, partially impacted by unfavorable foreign exchange. Companion animal products continue to be the primary revenue driver, accounting for approximately 68% of total revenue, with livestock products making up 31%. The company's top-selling products, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, remain significant contributors to overall revenue. Zoetis demonstrated effective cost management, with cost of sales as a percentage of revenue decreasing to 29.4% due to price increases, favorable product mix, and lower inventory and freight costs. Selling, general, and administrative expenses also saw an 8% increase, largely attributed to investments in compensation, selling, and promotional activities. Research and development expenses grew by 12%, reflecting continued investment in innovation and portfolio progression. The company also completed the divestiture of its medicated feed additive product portfolio in October 2024, which will impact future revenue streams. Zoetis remains committed to returning value to shareholders, evidenced by its completed $3.5 billion share repurchase program and a new $6 billion authorization, underscoring confidence in its future performance.

Feb 13, 2025 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 6, 2025)

Zoetis Inc. (ZTS) has filed an 8-K report on February 6, 2025, primarily disclosing the declaration of its second quarter 2025 dividend. Investors will note that the company has declared a dividend of $0.500 per share, payable on June 3, 2025, to shareholders of record as of April 21, 2025. This announcement, made via a press release on February 6, 2025, provides a clear signal of the company's ongoing commitment to returning capital to its shareholders.

Feb 6, 2025 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Jan 13, 2025)

Zoetis Inc. (ZTS) filed this Form 8-K under Regulation FD to furnish presentation materials for management's appearance at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The filing itself contains no new financial results, guidance changes, or material events; its substance lies in the furnished slide deck (Exhibit 99.1), which is not deemed 'filed' under the Exchange Act. The presentation reports strong year-to-date performance through Q3 2024: revenue of $6.9B growing 12% operationally, adjusted net income of $2.1B up 16% operationally, and adjusted diluted EPS of $4.52 up 18% operationally. Management highlighted the Librela and Solensia franchises, the Simparica family, and the Apoquel/Cytopoint dermatology franchise as key growth drivers, and cited $1.9B in capital returned to shareholders alongside the divestiture of the Medicated Feed Additive portfolio. Looking forward, management reiterated a three-to-five-year outlook targeting mid-to-high single-digit annual revenue growth, ROIC accretion, and margin improvement, and outlined a pipeline of conditional approvals and launches for 2025, along with expansion into new therapeutic areas (renal, oncology, cardiology). Investors should note that the presentation's projections are forward-looking, rely on internal estimates and industry data, and are subject to the risks listed in the company's 10-K and 10-Q filings.

Jan 13, 2025 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 12, 2024)

Zoetis Inc. (ZTS) announced on December 12, 2024, the declaration of its first-quarter 2025 dividend. This regular dividend payment demonstrates the company's continued commitment to returning capital to shareholders, a sign of financial stability and confidence in ongoing operations. The dividend amount is set at $0.500 per share, with a payment date of March 4, 2025, for shareholders of record as of January 21, 2025. While this filing is primarily for the disclosure of the dividend, it's important for investors to note that this information is furnished under Regulation FD and is not considered "filed" for the purposes of the Securities Exchange Act of 1934. This means it doesn't automatically become part of future SEC filings unless specifically incorporated. Investors seeking further details on Zoetis's financial performance and strategic outlook should refer to other filings and communications from the company.

Dec 12, 2024 8-K

Zoetis Inc. 8-K Report, Change in Control (Nov 12, 2024)

On November 11, 2024, Zoetis Inc. (NYSE: ZTS) announced a set of senior leadership changes, filed under Items 5.02 and 8.01 of Form 8-K. The most significant change is the creation of a new Chief Commercial Officer role, to which Jamie Brannan, previously EVP and Group President of International Operations, Aquaculture and Global Diagnostics, has been appointed effective immediately. He will oversee commercial operations across all global markets, including the United States and all International markets, signaling an intent to consolidate commercial leadership and drive greater global collaboration as the company pursues its next phase of growth. Several executive transitions accompany the reorganization. Chief Digital & Technology Officer Wafaa Mamilli will leave in early 2025 to pursue an external opportunity, and Keith Sarbaugh, who joined in March 2023, has been promoted to EVP and Chief Digital & Technology Officer, taking responsibility for technology, digital, data and analytics strategy. Ester Banque, President of U.S. Operations, is also departing and will serve in an advisory capacity until early 2025; Jared Shriver, a nearly 20-year Zoetis veteran, has been promoted to President, U.S. Operations, reporting to Mr. Brannan. For investors, the filing contains no financial results, guidance, or quantitative disclosures. The key takeaways are management-level: the U.S. business, a major revenue contributor, is changing leadership, and the company is restructuring its commercial organization and digital leadership simultaneously. Investors will likely watch whether these changes support continued growth and whether the transitions are executed smoothly, particularly given Ms. Banque's prior role in delivering above-market U.S. performance and Ms. Mamilli's oversight of China, Brazil and precision animal health.

Nov 12, 2024 10-Q

Zoetis Inc. Quarterly Report for Q3 Ended Sep 30, 2024

Zoetis Inc. reported strong financial results for the third quarter and the first nine months of 2024, demonstrating robust revenue growth driven by both price increases and product volume. For the three months ended September 30, 2024, total revenue increased by 11% year-over-year to $2.39 billion, with a 14% operational increase excluding foreign exchange impacts. Net income attributable to Zoetis Inc. grew by 14% to $682 million. For the nine-month period, revenue rose by 10% to $6.94 billion, and net income increased by 5% to $1.91 billion. The company's growth was propelled by its companion animal segment, particularly new products like Librela® and Solensia®, alongside strong performance in dermatology and parasiticides. While the company faces ongoing investments in R&D and SG&A, its cost management and operational efficiencies have contributed to sustained profitability. Zoetis also repurchased shares and declared dividends, indicating confidence in its financial health and commitment to returning value to shareholders.

Nov 4, 2024 8-K

Zoetis Inc. 8-K Report, Financial Results (Nov 4, 2024)

Zoetis (NYSE: ZTS) reported third quarter 2024 results on November 4, 2024 that beat the quarter on the top line and raised full-year 2024 revenue and adjusted EPS guidance. Q3 revenue was $2.39 billion, up 11% reported and 14% on an operational (FX-neutral) basis, driven by 18% U.S. companion animal growth, led by the osteoarthritis pain mAbs Librela and Solensia, Simparica Trio, and dermatology products. GAAP net income was $682 million, or $1.50 per diluted share (up 16%), while adjusted diluted EPS was $1.58 (up 16% reported, 17% operational) after excluding $34 million of purchase accounting, acquisition/divestiture, and certain significant items. Management raised full-year 2024 revenue guidance to $9.200-$9.300 billion (from $9.100-$9.250 billion), implying 10-11% operational growth, and raised adjusted diluted EPS guidance to $5.86-$5.92 (from $5.78-$5.88). Adjusted net income guidance was lifted to $2.670-$2.695 billion. Reported diluted EPS guidance is $5.33-$5.39, with the gap to adjusted EPS driven by roughly $0.29 of significant items and acquisition/divestiture costs and about $0.24 of purchase accounting. Adjusted SG&A and R&D guidance also moved higher, reflecting reinvestment alongside the top-line raise. Investors should note that the company completed the divestiture of its medicated feed additive portfolio to Phibro Animal Health on October 31, 2024, which management frames as capital reallocation toward vaccines, biologics, and genetics in livestock. Growth is strongest in U.S. companion animal products, while International growth on a reported basis was muted at 7% because of foreign exchange headwinds (-6%), and China revenue declined 12%. The financial figures in this release are unaudited, and the information is furnished under Item 2.02 rather than filed.

Nov 4, 2024 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 10, 2024)

Zoetis Inc. (ZTS) has filed an 8-K report on October 10, 2024, primarily announcing its fourth-quarter 2024 dividend. The Board of Directors declared a dividend of $0.432 per share, demonstrating a consistent commitment to returning capital to shareholders. This dividend is scheduled to be paid on December 3, 2024, to shareholders of record as of October 31, 2024. While this filing is routine and does not contain significant operational or financial updates, the dividend declaration is a key piece of information for income-focused investors. It signals continued financial stability and management's confidence in the company's ability to generate sufficient cash flow to support its dividend payout policy.

Oct 10, 2024 10-Q

Zoetis Inc. Quarterly Report for Q2 Ended Jun 30, 2024

Zoetis Inc. (ZTS) reported strong top-line growth for the second quarter and first half of 2024, with total revenue increasing by 8% and 9% respectively, driven by a combination of price increases and volume growth in key product categories like dermatology and new products. Operationally, revenue growth was even more robust, up 11% for the quarter and 12% for the half-year, indicating underlying business strength despite unfavorable foreign exchange impacts. Profitability saw a decline in reported net income for the quarter, primarily due to higher restructuring and divestiture-related costs and other (income)/deductions—net, which included a significant loss on assets held for sale. However, excluding these items, adjusted net income and adjusted diluted EPS showed healthy year-over-year increases, demonstrating continued operational efficiency and profitability.

Aug 6, 2024 8-K

Zoetis Inc. 8-K Report, Financial Results (Aug 6, 2024)

Zoetis (NYSE: ZTS) reported second quarter 2024 results on August 6, 2024, delivering revenue of $2.36 billion, up 8% on a reported basis and 11% on an operational (currency-neutral) basis. Reported net income was $624 million, or $1.37 per diluted share, down 7% and 6% respectively, largely reflecting higher operating costs, R&D spending, and a swing from a prior-year $101 million gain on the sale of a pet insurance business. On a non-GAAP adjusted basis, net income rose 9% to $711 million, or $1.56 per diluted share (up 11%), and grew 18% operationally, a stronger picture of underlying profitability. Growth was led by the U.S. (up 12%) and companion animal products, notably osteoarthritis pain mAbs Librela and Solensia, Simparica Trio, and dermatology products Apoquel and Cytopoint. Management raised full-year 2024 guidance, now calling for revenue of $9.100 to $9.250 billion (9% to 11% operational growth), adjusted net income of $2.640 to $2.690 billion (13.5% to 15.5% operational growth), and adjusted diluted EPS of $5.78 to $5.88. Reported diluted EPS guidance is $5.35 to $5.45, with the gap driven primarily by roughly $80 to $90 million of certain significant items and acquisition/divestiture costs and about $110 million of purchase accounting adjustments. The guidance reflects foreign exchange rates as of late July 2024. Investors should note that international operational growth of 10% contrasted with a 6% headwind from currency, and that the company relies heavily on non-GAAP measures, which the filing reconciles to GAAP figures.

Aug 6, 2024 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Aug 1, 2024)

On August 1, 2024, Zoetis Inc. (NYSE: ZTS) announced that its Board of Directors approved a new multi-year share repurchase program authorizing the company to buy back up to $6 billion of its common stock. The program has no expiration date, does not obligate Zoetis to make any purchases, and may be terminated, increased, or decreased by the Board at any time. Repurchases may be made through open market or privately negotiated transactions. Management indicated the shares are expected to be repurchased over a period of up to four years. The authorization is described as the largest share repurchase program in Zoetis's history and is framed by management as a signal of confidence in the company's long-term outlook and continued cash flow generation. CFO Wetteny Joseph characterized the program as reinforcing the company's commitment to its value proposition, and the press release ties it to a disciplined capital allocation strategy that balances reinvestment in growth with returns to shareholders. The new authorization arrives as the prior $3.5 billion program, approved in December 2021, is expected to be completed in 2024. Investors should note that the filing is a board authorization rather than a commitment to specific purchase volumes or timing, so actual buybacks will depend on future capital needs, cash generation, and market conditions. The filing also reports 2023 revenue of approximately $8.5 billion and roughly 14,100 employees for context.

Aug 1, 2024 8-K

Zoetis Inc. 8-K Report, Executive Changes (May 24, 2024)

Zoetis Inc. (ZTS) has filed an 8-K report detailing changes related to Heidi C. Chen's employment. Ms. Chen, previously a corporate officer, will continue with the company in a non-officer capacity until July 16, 2024, receiving her current salary and benefits. Following this date, she will transition to a non-employee consultant role until December 31, 2024. This transition includes specific compensation arrangements. Ms. Chen will receive a $350,000 consulting fee for her advisory services, contingent on her compliance with the agreement and execution of a release. She is also eligible for severance payments and benefits under the existing Zoetis Executive Severance Plan. Investors should note this is primarily an operational update regarding an executive transition, with no immediate impact on financial performance or strategic direction reported in this filing.

May 24, 2024 8-K

Zoetis Inc. 8-K Report, Executive Changes (May 23, 2024)

Zoetis Inc. (ZTS) filed an 8-K on May 22, 2024, detailing the outcomes of its Annual Meeting of Shareholders held on May 20, 2024. Key events include the retirement of Dr. Linda Rhodes from the Board of Directors and shareholder approval of an amendment to the Restated Certificate of Incorporation to provide exculpation for certain officers, which became effective on May 22, 2024. The Annual Meeting saw high shareholder participation, with nearly 90% of voting power represented. Investors will note that all twelve director nominees were re-elected for one-year terms, and the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 was ratified. The company's executive compensation program received advisory approval, indicating shareholder confidence in the current remuneration structure. However, a shareholder proposal concerning the director resignation policy was not approved.

May 23, 2024 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 22, 2024)

Zoetis Inc. (ZTS) has filed an 8-K report on May 22, 2024, primarily disclosing its third quarter 2024 dividend. The company declared a dividend of $0.432 per share, which is scheduled to be paid on September 4, 2024, to shareholders of record as of July 18, 2024. This announcement provides a clear indication of the company's commitment to returning capital to its shareholders and offers a tangible return for investors holding the stock through the specified record date.

May 22, 2024 10-Q

Zoetis Inc. Quarterly Report for Q1 Ended Mar 31, 2024

Zoetis Inc. reported strong financial results for the first quarter of 2024, with total revenue increasing by 10% to $2.19 billion compared to the same period in 2023. This growth was driven by a solid 12% increase on an operational basis, primarily attributed to price increases (7%), new product volume (4%), and key dermatology product volume (3%). Net income attributable to Zoetis Inc. rose by 9% to $599 million, with diluted earnings per share increasing from $1.19 to $1.31. The company's performance highlights the strength and resilience of the animal health market, with notable growth in companion animal products, particularly in the U.S. segment. The International segment also showed positive operational growth despite currency headwinds. Zoetis continues to invest in research and development to fuel future innovation and maintain its market leadership.

May 2, 2024 8-K

Zoetis Inc. 8-K Report, Financial Results (May 2, 2024)

Zoetis Inc. (NYSE: ZTS) reported first quarter 2024 results on May 2, 2024, with revenue of $2.19 billion, up 10% reported and 12% on an operational (constant-currency) basis. Reported net income was $599 million, or $1.31 per diluted share, up 9% and 10% respectively. Adjusted net income, which excludes purchase accounting adjustments, acquisition-related costs and certain significant items, was $634 million, or $1.38 per diluted share, up 4% and 5% on a reported basis and 15% and 17% operationally. Growth was led by the U.S. segment, where revenue rose 16% and companion animal sales rose 25%, driven by Simparica Trio, Apoquel/Cytopoint and the osteoarthritis pain products Librela and Solensia. International revenue grew 3% reported and 8% operationally, while livestock revenue declined 5% reported and 1% operationally, with weakness in swine, sheep and cattle. Zoetis raised its full-year 2024 operational revenue growth outlook to 8.5%-10.5% and its operational adjusted net income growth outlook to 13%-15%. Revenue guidance is $9.050-$9.200 billion. Reported diluted EPS guidance is $5.34-$5.44 and adjusted diluted EPS guidance is $5.71-$5.81. Management attributed the operational increase to inflation-related price increases in Argentina and continued strength in companion animal. The guidance reflects foreign exchange rates as of late April 2024, so the reported figures remain exposed to currency movements. The company also disclosed a agreement to sell its medicated feed additive (MFA) portfolio, announced April 28, 2024, to concentrate investment on vaccines, biologics and genetic livestock programs. It also agreed to buy a manufacturing site in Melbourne, Australia. Investors will likely focus on the sustainability of companion animal growth, the drag from livestock and China, and the gap between reported and adjusted EPS.

May 2, 2024 8-K

Zoetis Inc. 8-K Report, Executive Changes (Apr 16, 2024)

Zoetis Inc. announced a significant leadership change, with Executive Vice President, General Counsel and Corporate Secretary, Heidi C. Chen, departing from her executive roles effective April 16, 2024. Ms. Chen will transition to an employee advisor role until July 16, 2024, and is expected to continue as a non-employee consultant thereafter. This departure marks a shift in the company's legal and corporate governance leadership. In response to Ms. Chen's departure, Roxanne Lagano, EVP, Chief Human Resources Officer and Global Operations, will assume the interim responsibilities of General Counsel and Corporate Secretary. Zoetis is actively searching for a permanent replacement, considering both internal and external candidates. Investors should note that Ms. Chen is eligible for severance benefits under the company's existing Executive Severance Plan and also qualifies for retirement-eligible benefits, as detailed in the company's recent Proxy Statement.

Apr 16, 2024 8-K

Zoetis Inc. 8-K Report, Executive Changes (Apr 1, 2024)

Zoetis Inc. (NYSE: ZTS) filed a Form 8-K on April 1, 2024 to disclose a board change: Gavin D.K. Hattersley, President and CEO of Molson Coors Beverage Company, was appointed to the Board of Directors. The Board expanded from twelve to thirteen members, and Mr. Hattersley will serve on the Corporate Governance and Sustainability Committee. The filing describes the appointment as unrelated to any third-party arrangement and reports no reportable related-party transactions under Item 404(a) of Regulation S-K. The filing is a governance event rather than a financial one. It contains no earnings, guidance, financial statements, or material transactions, and the filing states no change in financial results. Mr. Hattersley's compensation will follow the non-employee director program described in Zoetis's preliminary 2024 proxy statement filed March 27, 2024, and he entered the company's standard indemnification agreement, which was previously filed as an exhibit to a 2012 Form S-1 amendment. For investors, the main significance is the addition of an experienced public-company CEO and former CFO with a background in brewing, manufacturing, and corporate development. The company frames this as support for its growth in key global markets and its strategy as a diversified animal health company. The filing does not disclose any operational impact, and the appointment should be viewed as a routine but positive governance update.

Apr 1, 2024 10-K

Zoetis Inc. Annual Report, Year Ended Dec 31, 2023

Zoetis Inc. (ZTS) reported a solid performance in its 2023 10-K filing, demonstrating consistent revenue growth driven by both price increases and volume from new products. The company maintains a diversified portfolio across companion animal and livestock segments, with companion animal products representing a larger portion of revenue. Key therapeutic areas like parasiticides, dermatology, and vaccines continue to be strong contributors. Zoetis's strategic focus on innovation, customer experience, and digital solutions is evident in its R&D investments and product lifecycle management. The company also highlighted its commitment to sustainability and employee well-being, reflected in its human capital management initiatives and decreasing voluntary attrition rate. Despite some challenges like supply chain constraints and increasing competition, Zoetis's financial health remains robust, supported by strong operating cash flow and a healthy balance sheet, allowing for continued investment in growth and shareholder returns through share repurchases and dividends.

Feb 13, 2024 8-K

Zoetis Inc. 8-K Report, Financial Results (Feb 13, 2024)

Zoetis Inc. (NYSE: ZTS) reported fourth quarter and full year 2023 results on February 13, 2024, and issued full year 2024 guidance. Fourth quarter revenue was $2.2 billion, up 8% on both reported and operational bases, while reported net income rose 14% to $525 million ($1.14 per diluted share). Adjusted net income of $569 million ($1.24 per diluted share) grew 6% reported and 8% per share on a reported basis, with operational growth of 6% in adjusted net income. For full year 2023, revenue reached $8.5 billion (up 6% reported, 7% operational), and reported net income was $2.3 billion ($5.07 per diluted share). Adjusted net income was $2.5 billion ($5.32 per diluted share), growing 7% operationally. Growth was led by companion animal franchises, particularly the osteoarthritis pain monoclonal antibodies Librela (dogs) and Solensia (cats), along with dermatology and parasiticide products. Management guided to full year 2024 revenue of $9.075 to $9.225 billion, representing 7% to 9% operational growth, with reported diluted EPS of $5.34 to $5.44 and adjusted diluted EPS of $5.74 to $5.84. Adjusted net income is expected to grow 9% to 11% operationally. The guidance reflects foreign exchange rates as of late January 2024. Management emphasized Librela as a path to its next billion-dollar franchise. Segment detail shows U.S. revenue up 9% in the quarter, while International revenue rose 9% reported and 8% operationally, with China notably weak, down 29% in the quarter and 16% for the year. For investors, the results show consistent operational growth and margin pressure from higher adjusted cost of sales as a percentage of revenue in the quarter, which rose to 32.9% from 31.9%. Guidance implies continued top-line expansion alongside a modest margin recovery in 2024. The 8-K furnishes the press release under Item 2.02 and is not deemed filed for Exchange Act liability purposes.

Feb 13, 2024 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 6, 2024)

Zoetis Inc. (ZTS) filed an 8-K on February 6, 2024, primarily to disclose its second quarter 2024 dividend declaration. The company announced a quarterly dividend of $0.432 per share, payable on June 4, 2024, to shareholders of record as of April 19, 2024. This announcement reflects the company's ongoing commitment to returning capital to shareholders. While this filing is limited in scope and does not contain comprehensive financial updates or material business developments, the dividend declaration signals continued confidence from management in the company's financial health and its ability to generate consistent cash flows. Investors focused on income generation and capital return policies will find this information pertinent.

Feb 6, 2024 8-K

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 7, 2023)

Zoetis Inc. (ZTS) filed an 8-K on December 7, 2023, primarily announcing its first-quarter 2024 dividend. The company declared a dividend of $0.432 per share, payable on March 1, 2024, to shareholders of record as of January 19, 2024. This action signals continued confidence in the company's financial health and its commitment to returning value to shareholders.

Dec 7, 2023